GgoogleMX first seen 5 d ago, last 5 d ago, peak #1

BMS scores pivotal trial win for admilparant in IPF

Original: tumor

Bristol Myers Squibb has reported a pivotal trial win for admilparant, an investigational treatment for idiopathic pulmonary fibrosis. The positive result marks a significant milestone for the drug's development, and pharma industry watchers are taking note of what it could mean for patients with the progressive lung disease and for the company's pipeline.

Why now: The positive pivotal trial result is fresh industry news drawing attention from pharma watchers.

Bristol Myers Squibbadmilparantidiopathic pulmonary fibrosis

Open on google →

Rank over time, top of the chart is #1. 3 snapshots from 5 d ago to 5 d ago.

Evidence

• RYZ101 Improves Progression-Free Survival in Previously Treated GEP-NETs · CancerNetwork
• BMS scores pivotal trial win for admilparant in IPF · FirstWord Pharma

API: https://socialmediatrends-api.osmike.com/v1/trends/1998018